Skip to Main Content

When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic? And how do you edit a chicken?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We also explain the latest news in the life sciences, including Wall Street’s freakout over GLP-1, CRISPR’ing animals, and the latest in the NASH saga.


For more on what we cover, here’s the news on Mirati; here’s more on biotech venture capital; here’s the latest on Alnylam Pharmaceuticals; here’s more on NASH; here’s the story on xenotransplantation; here’s more on genome-edited chickens; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!

To submit a correction request, please visit our Contact Us page.